|
|
British Journal of Cancer (2006) 94, 465-468.
doi:10.1038/sj.bjc.6602963 Published online 31 January 2006
Targeting insulin-like growth factor pathways
D Yee1
1University of Minnesota Cancer Center, Department of Medicine, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Correspondence to: Dr D Yee, E-mail: yeexx006@umn.edu
Received 9 November 2005; revised 20 December 2005; accepted 21 December 2005; published online 31 January 2006
Some cancer cells depend on the function of specific molecules for their growth, survival, and metastatic potential. Targeting of these critical molecules has arguably been the best therapy for cancer as demonstrated by the success of tamoxifen and trastuzumab in breast cancer. This review will evaluate the type I IGF receptor (IGF-IR) as a potential target for cancer therapy. As new drugs come forward targeting this receptor system, several issues will need to be addressed in the early clinical trials using these agents.
Keywords: insulin-like growth factors; insulin-like growth factor receptors; monoclonal antibodies; tyrosine kinase inhibitors
back to top  |
| Article links | |
| ||
| ||
 | Send to a friend | |
 | Download PDF | |
| ||
| ||
| ||
 | Full text | |
| ||
| ||
| ||
 | Preceding article | |
 | Next article | |
 | Table of Contents | |
| ||
| ||
| ||
| ||
| ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2006 Cancer Research UK | ||
| |||
| Privacy Policy | |||